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LETTERS
This report demonstrates an ap-
parently paradoxical inverse relation-
ship between a positive RDT result 
and severity of illness among patients 
with pandemic (H1N1) 2009. This 
observation cannot be explained by 
differences in the time to access to 
medical care, performance of RDT 
(7), or prior antiviral therapy. Variants 
of pandemic (H1N1) 2009 virus may 
preferentially infect the lower respira-
tory tract in certain hosts (8). Invasive 
properties of pandemic (H1N1) 2009 
virus and severity of illness may be 
more closely related to heterogeneity 
in host immunity than to viral load 
(9). US Centers for Disease Control 
and Prevention guidance advises that 
“hospitalized patients with suspected 
inﬂ   uenza should receive immediate 
empiric antiviral treatment…, a nega-
tive RIDT or DFA test result does not 
exclude inﬂ   uenza virus infection…” 
(10). Moreover, this guidance also 
recommends that collection of lower 
respiratory tract specimens may be 
useful for reverse transcription–PCR 
testing to improve diagnosis for pa-
tients suspected of having severe 
lower respiratory tract disease caused 
by pandemic (H1N1) 2009 virus. The 
current ﬁ  ndings strongly support this 
recommendation, particularly for se-
verely ill patients.
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Human Brucella 
canis Infections 
Diagnosed by 
Blood Culture
To the Editor: Brucellosis is a 
worldwide zoonosis caused by Brucel-
la spp. The 4 species known to infect 
humans are B. melitensis, B. suis, B. 
abortus, and B. canis (1). Since 1999, 
11 cases in Japan have been reported. 
Although no bacteria were isolated, se-
rum antibody detection indicated that 
4 were caused by B. melitensis or B. 
abortus acquired abroad and the other 
7 by B. canis (2). Of these 7 patients, 2 
were presumed to have received their 
infection from dogs, and the sources 
of infection for the other 5 are unclear. 
We report 2 cases of B. canis infection 
diagnosed by blood culture.
Patient 1 was a 71-year-old male 
pet shop manager with hypertension. 
He came to Chubu Rosai Hospital, 
Nagoya, Japan, on August 9, 2008, 
after having fever and fatigue for 3 
weeks, which were nonresponsive to 
third-generation cephalosporins. At 
the time of admission, his temperature 
was 37.8°C, but physical examination 
ﬁ  ndings were unremarkable. On day 
2, gram-negative coccobacilli were 
detected in a culture of blood collected 
at the time of admission. Ceftriaxone 
(1 g 1×/d) was administered, but fever 
persisted. On day 5, coccobacilli were 
growing poorly on culture media. Be-
cause the patient’s history indicated 
the possibility of a zoonotic disease, 
doxycycline (100 mg 2×/d) was ad-
ministered. Thereafter, the patient’s 
fever and generalized symptoms re-
solved. The blood specimen and iso-
lated bacteria were sent to the Na-
tional Institute of Infectious Disease, 
B. canis was identiﬁ  ed by combinato-
rial PCR (3). Serum tube agglutination 
test indicated an antibody titer against 
B. canis of 1,280 (Table). On day 10, 
streptomycin (1 g 1×/d) was added to 
the treatment regimen. On day 33, the 
patient was discharged; his laboratory 
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values were almost within reference 
limits, and he continued taking doxy-
cycline for 6 weeks and streptomycin 
for 2 weeks.
Patient 2, a previously healthy 
44-year-old co-worker of patient 1, 
exhibited similar signs and symp-
toms—fever and general fatigue—
that started around the same time as 
for patient 1 (3 weeks before August 
9, 2008). Physical examination ﬁ  nd-
ings at that time were unremarkable. 
Blood tests indicated moderate liver 
dysfunction. Treatment with fosfomy-
cin was not effective. On August 19, 
the day after the diagnosis of brucel-
losis was made for patient 1, patient 2 
came to Chubu Rosai Hospital, where 
B. canis was identiﬁ   ed from blood 
culture. Serum antibody titer was 
320 (Table). This patient was treated 
with doxycycline (100 mg 2×/d) plus 
rifampin (600 mg 1×/d) for 6 weeks. 
All signs, symptoms, and liver dys-
function resolved.
Neither patient had an immune 
disorder. About 2 months before ill-
ness onset they had each handled, 
without protection, the placenta of an 
aborted dog fetus. Negative antibody 
results were obtained for other persons 
at risk for infection: laboratory work-
ers who were exposed to the patients’ 
specimens, the patients’ families, and 
a veterinarian who had been stuck by 
a needle when collecting blood from 
pet shop dogs to examine for antibody 
against B. canis. We prescribed doxy-
cycline plus rifampin for 3 laboratory 
workers because brucellosis is among 
the most commonly reported labora-
tory-acquired bacterial infections and 
because postexposure prophylaxis is 
recommended for persons at high risk 
for exposure (4).
Several days after identiﬁ  cation 
of B. canis for patient 1, the dogs in 
the pet shop (37 dogs, 23 adults and 
their 14 puppies) were examined for 
antibody against B. canis by using 
the microplate agglutination test (5) 
and for the B. canis  –speciﬁ  c gene by 
combinatorial PCR (3). A total of 6 
dogs were positive for antibody (titers 
320–5,120) and the speciﬁ  c gene; 5 
were positive for antibody only (titers 
320–5,120), and 4 were positive for 
the speciﬁ  c gene only. Only adult dogs 
had positive results. Blood cultures 
were positive for 6 dogs that were an-
tibody positive. Dogs that were deter-
mined by any method to be infected 
and their puppies (with negative test 
results) were euthanized. Since Janu-
ary 2008, a total of 8 puppies from the 
infected dogs had been sold; they were 
located, tested, and found to not have 
antibody against B. canis. The local 
government reported this informa-
tion to the Ministry of Health, Labour 
and Welfare, Japan, and the ministry 
shared the information with related 
organizations.
Caution is necessary when basing 
diagnosis on serum tube agglutination 
test because B. canis has rough sur-
face antigen and does not cross-react 
with B. abortus antigen (smooth Bru-
cella spp.), which is usually used to 
diagnose brucellosis (1). Furthermore, 
because brucellosis is relatively rare 
and signs and symptoms are nonspe-
ciﬁ  c, the number of cases reported is 
thought to be underestimated (6–8). 
A recent report showed that 2.5% of 
dogs in Japan have antibody against 
B. canis, but adult dogs are rarely seri-
ously ill despite this generalized sys-
temic infection (5,9). Thus, if a febrile 
person has signs and symptoms of 
unknown cause and a history of close 
contact with dogs, brucellosis should 
be considered and appropriate action 
to prevent spread of infection should 
be taken.
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Oseltamivir-
Resistant Pandemic 
(H1N1) 2009 in 
Patient with 
Impaired Immune 
System
To the Editor: We detail the de-
velopment of oseltamivir-resistant 
pandemic (H1N1) 2009 in a chroni-
cally immunocompromised patient 
and the pitfalls encountered when 
treating such patients with neuramin-
idase inhibitors. On August 6, 2009, 
a 56-year-old man was seen in the 
emergency room of a local hospital 
with a 24-hour history of fever, my-
algia, coryzal symptoms, and cough. 
He was on day 3 of a postexposure 
course of oseltamivir (75 mg 1×/d); 
inﬂ  uenza A had been presumptively 
diagnosed for his wife after she had 
similar symptoms.
The patient’s medical history 
showed grade IVB nodular sclerosing 
Hodgkin lymphoma, which had been 
diagnosed in 2001. Lymphoma was 
initially treated with chemotherapy, 
but relapse required autologous pe-
ripheral stem cell transplantation in 
July 2005. Further relapses in 2006 
and 2007 were treated with radiother-
apy and chemotherapy, respectively, 
before the patient underwent an allo-
geneic peripheral stem cell transplan-
tation in July 2008. This treatment was 
complicated by graft-versus-host dis-
ease, and the patient required ongoing 
immunosuppression.
When hospitalized, the patient 
was being treated with cyclosporine 
A (50 mg/d) and prednisolone (20 
mg/d). Physical examination showed 
a temperature of 39°C and wheezing 
from the left lung. Initial tests showed 
a neutrophil count of 2.02 × 109/L, 
a lymphocyte count of 0.87 × 109/L, 
and a C-reactive protein level of 33 
mg/L. He was started on piperacillin–
tazobactam and gentamicin, and osel-
tamivir was increased to the treatment 
dose of 75 mg 2×/d. A nasopharyngeal 
aspirate collected on August 7 con-
tained pandemic (H1N1) 2009 viral 
RNA by real-time PCR for generic in-
ﬂ  uenza A (1) and capillary sequencing 
for subtype H1N1 (testing by Micro-
pathology Ltd, Coventry, UK). By Au-
gust 9, the patient was still febrile, and 
zanamivir (10 mg 2×/d) was started. 
Oseltamivir was given for a total of 7 
d and zanamivir for 3 d.
Nose and throat swabs taken on 
August 21 still contained pandemic 
(H1N1) 2009 viral RNA. Real-time 
PCR and pyrosequencing demonstrat-
ed a histidine-to-tyrosine substitution 
(H275Y) in the neuraminidase gene 
associated with oseltamivir resistance 
(Respiratory Virus Unit, Centre for 
Infections, Health Protection Agen-
cy; methods not in public domain). 
A mixture of wild-type and resistant 
virus was present (A. Lackenby, pers. 
comm.). The sample from August 7 
did not contain this mutation, suggest-
ing a de novo H275Y substitution sec-
ondary to oseltamivir use.
The patient improved and was 
discharged on August 23 but returned 
for treatment on September 7 with 
worsening fever and cough. Nose and 
throat swabs obtained on September 
11 were PCR negative, but follow-up 
samples on September 25 and Octo-
ber 1 contained detectable pandemic 
(H1N1) 2009 viral RNA. Because vi-
rus isolation was not performed, true 
infectivity remains unresolved, but in-
termittent detection suggests ongoing 
replication, such as that seen in other 
immunocompromised patients (2,3).
By February 3, 2010, a total of 
225 cases of oseltamivir-resistant pan-
demic (H1N1) 2009 had been identi-
ﬁ  ed worldwide; a high proportion of 
cases were in immunocompromised 
persons (4). A minority of these muta-
tions were detected in treatment-naive 
patients. Immunocompromised, par-
ticularly lymphopenic, patients shed 
virus for prolonged periods leading 
to longer treatment courses and viral 
shedding reviving on termination of 
treatment. Viral shedding for up to 
18 months has been reported for sea-
sonal inﬂ  uenza, which has important 
implications for infection control (5). 
Our patient demonstrated that a single 
PCR-negative test does not reliably 
determine the end of viral shedding, 
which continued despite co-treatment 
with 2 neuraminidase inhibitors. 
Neuraminidase inhibitors interfere 
with the release of progeny inﬂ  uenza 
virus from their infected host cells. Ef-
fective treatment depends partially on 
immune system destruction of the foci 
of infection (6), or potential persis-
tent viral particles can be released as 
soon as oseltamivir therapy is stopped. 
The low genetic barrier to oseltamivir 
means that resistance is a likely con-
sequence of monotherapy in immuno-
compromised patients.
Concern about oseltamivir resis-
tance has led to issuance of additional 
guidelines, especially in light of the 
transmission of resistant virus between 
immunocompromised patients on hos-
pital wards in the United States and 
Wales (7,8). This ﬁ  nding suggests that 
immunocompromised patients should 
be treated with oseltamivir and zana-
mivir, or with zanamivir alone, for a 
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